Estrella Immunopharma Inc. (ESLA) - Total Assets
Based on the latest financial reports, Estrella Immunopharma Inc. (ESLA) holds total assets worth $3.66 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net asset quality index of Estrella Immunopharma Inc. to measure how much of total assets are equity-financed.
Estrella Immunopharma Inc. - Total Assets Trend (2020–2025)
This chart illustrates how Estrella Immunopharma Inc.'s total assets have evolved over time, based on quarterly financial data. Check Estrella Immunopharma Inc. (ESLA) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Estrella Immunopharma Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Estrella Immunopharma Inc.'s total assets of $3.66 Million consist of 52.8% current assets and 47.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 43.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Estrella Immunopharma Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ESLA market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Estrella Immunopharma Inc.'s current assets represent 52.8% of total assets in 2025, an increase from 0.0% in 2020.
- Cash Position: Cash and equivalents constituted 43.6% of total assets in 2025, up from 0.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Estrella Immunopharma Inc. Competitors by Total Assets
Key competitors of Estrella Immunopharma Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €8.68 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩703.48 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
|
USA | $452.70 Million |
|
Tourmaline Bio Inc.
NASDAQ:TRML
|
USA | $269.30 Million |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230
|
China | CN¥1.32 Billion |
Estrella Immunopharma Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.24 | 0.22 | 0.06 |
| Quick Ratio | 0.24 | 0.22 | 0.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-6.77 Million | $-3.33 Million | $-216.48K |
Estrella Immunopharma Inc. - Advanced Valuation Insights
This section examines the relationship between Estrella Immunopharma Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.13 |
| Latest Market Cap to Assets Ratio | 13.55 |
| Asset Growth Rate (YoY) | 1.2% |
| Total Assets | $3.18 Million |
| Market Capitalization | $43.03 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Estrella Immunopharma Inc.'s assets at a significant premium (13.55x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Estrella Immunopharma Inc.'s assets grew by 1.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Estrella Immunopharma Inc. (2020–2025)
The table below shows the annual total assets of Estrella Immunopharma Inc. from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $3.18 Million | +1.15% |
| 2024-12-31 | $3.14 Million | -29.49% |
| 2023-12-31 | $4.45 Million | -55.40% |
| 2022-12-31 | $9.99 Million | +102.91% |
| 2021-12-31 | $4.92 Million | -- |
| 2020-12-31 | $0.00 | -- |
About Estrella Immunopharma Inc.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leuke… Read more